Last reviewed · How we verify

Fundación Huésped — Portfolio Competitive Intelligence Brief

Fundación Huésped pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lopinavir/ritonavir simplification strategy Lopinavir/ritonavir simplification strategy marketed Protease inhibitor combination HIV protease Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 shared drug class
  2. National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
  3. University of Chicago · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Huésped:

Cite this brief

Drug Landscape (2026). Fundación Huésped — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-hu-sped. Accessed 2026-05-16.

Related